The clinical phase III trials of the COVID-19 nasal vaccine have been completed and the company will submit its data with Drugs Controller General of India (DCGI) next month, Dr Krishna Ella, Chairman and Managing Director of Bharat Biotech has said.
Krishna was in Paris as a speaker at Viva Technology 2022.
Dr Ella told ANI in an exclusive interview: “We just completed a clinical trial, a data analysis is going on. Next month, we will submit the data to the regulatory agency. If everything is okay, then we will get permission to launch and it will be the world’s first clinically proven nasal Covid-19 vaccine”.
In January 2022, India’s drug controller had given permission to Bharat Biotech to conduct standalone phase III trials on its Covid-19 nasal vaccine.
(Agencies; Picture Courtesy: ANI)